Anebulo Pharmaceuticals, Inc. (ANEB): Price and Financial Metrics


Anebulo Pharmaceuticals, Inc. (ANEB): $2.94

-0.04 (-1.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANEB to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ANEB Stock Price Chart Interactive Chart >

Price chart for ANEB

ANEB Price/Volume Stats

Current price $2.94 52-week high $8.70
Prev. close $2.98 52-week low $2.75
Day low $2.75 Volume 1,700
Day high $2.94 Avg. volume 5,778
50-day MA $5.14 Dividend yield N/A
200-day MA $6.42 Market Cap 68.63M

Anebulo Pharmaceuticals, Inc. (ANEB) Company Bio


Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients suffering from cannabinoid overdose and addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.


ANEB Latest News Stream


Event/Time News Detail
Loading, please wait...

ANEB Latest Social Stream


Loading social stream, please wait...

View Full ANEB Social Stream

Latest ANEB News From Around the Web

Below are the latest news stories about Anebulo Pharmaceuticals Inc that investors may wish to consider to help them evaluate ANEB as an investment opportunity.

Anebulo Pharmaceuticals GAAP EPS of -$0.05

Anebulo Pharmaceuticals press release (ANEB): Q2 GAAP EPS of -$0.05.Cash and cash equivalents were $18M as of December 31, 2021

Seeking Alpha | February 11, 2022

Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates

AUSTIN, Texas--(BUSINESS WIRE)---- $ANEB #ANEB--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended December 31, 2021 and recent updates. Highlights from the fiscal year 2022 second quarter and recent weeks include the following: Initiated a Phase 2 proof-of-concept clinical study t

Business Wire | February 11, 2022

We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Yahoo | February 4, 2022

Anebulo Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference

AUSTIN, Texas, January 06, 2022--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the presentation will be available on-demand beginning January 10, 2022 at 7:00 a.m. Eastern time on the Investors se

Yahoo | January 6, 2022

Anebulo Pharmaceuticals Appoints Scott L. Anderson as Head of Investor Relations and Public Relations

AUSTIN, Texas, January 06, 2022--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, announced today that it has appointed Scott L. Anderson as Head of Investor Relations and Public Relations, effective immediately.

Yahoo | January 6, 2022

Read More 'ANEB' Stories Here

ANEB Price Returns

1-mo -26.87%
3-mo -58.00%
6-mo -53.11%
1-year -63.25%
3-year N/A
5-year N/A
YTD N/A
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.072 seconds.